Patient Information:
	•Name: David Bielecki
	•Date of Birth: 01/15/1970
	•Medical Record Number: M1424
	•Date of Admission: 10/31/2022
	•Date of Discharge: 12/10/2022
	•Attending Physician: Dr. Richard Bielecki
	•Primary Diagnosis: Stage IIIB Colorectal Cancer with liver metastasis

Reason for Admission:
	David Bielecki was admitted to our hospital on October 31, 2022, following a diagnosis of David Bielecki David Bielecki with liver metastasis. He presented with symptoms of abdominal pain, weight loss, and fatigue over the past three months. Upon initial assessment, David exhibited signs of anemia, abnormal stool pattern, and palpable abdominal masses. Subsequent laboratory investigations confirmed a high carcinoembryonic antigen (CEA) level, positive fecal occult blood test, and colonoscopy findings indicating advanced colorectal cancer. Further diagnostic imaging, including computed tomography (CT), revealed the presence of liver metastasis.

Medical History:
	David has a past medical history significant for hypertension, type 2 diabetes mellitus, and chronic obstructive pulmonary disease (COPD). He underwent a laparoscopic cholecystectomy in 2015 due to gallstones. His family history is noteworthy for breast cancer, with his mother being diagnosed at the age of 58. David has known allergies to penicillin and iodinated contrast dye. Prior to admission, he was taking metformin, lisinopril, and albuterol as prescribed medications.

Diagnostic Findings:
	Pathology results from the biopsy of the primary colorectal tumor revealed moderately differentiated adenocarcinoma, with a high proliferation index (Ki-67 30%). CT scans showed a large mass in the right colon and multiple liver metastases. The staging of the cancer was confirmed as T4N2M1 (David Bielecki). Additionally, laboratory tests revealed anemia (Hb 8 g/dL), elevated CEA level (150 ng/mL), and abnormal liver function tests.

Treatment Plan:
	A multidisciplinary team developed a comprehensive treatment plan for David, consisting of a partial colectomy with an ileal conduit creation, post-operative chemotherapy, and radiation therapy to the liver metastasis sites. The surgical intervention was performed successfully on November 5, 2022. Post-operative care included pain management, wound care, and nutritional support through a nasogastric tube.

Hospital Course:
	

Follow-Up Plan:
	David's follow-up plan includes scheduled outpatient appointments every three months for physical examination, CEA level monitoring, and CT scans to assess tumor response and monitor for recurrence. He will continue on oral chemotherapy (Capecitabine) as prescribed. Lifestyle recommendations include maintaining a balanced diet, regular exercise, and avoiding tobacco products.

Patient Education:
	David and his family were provided extensive education on post-surgical care, management of the ileal conduit, recognizing signs of complications such as obstruction or infection, and managing common side effects like diarrhea, neuropathy, and fatigue. They were also instructed on proper wound care practices, hydration, and physical activity guidelines to aid in recovery.

Discharge Instructions:
	David was discharged with a clear understanding of his medication regimen, including Capecitabine, metformin, lisinopril, and albuterol. He was advised on proper wound care practices, hydration, and physical activity guidelines to promote healing and minimize the risk of complications.

Prognosis and Long-Term Outlook:
	Regular monitoring for early detection of recurrence is crucial in managing David's long-term health issues. It is essential that he adheres to his medication regimen, maintains a healthy lifestyle, and seeks immediate medical attention if any warning signs arise.

Final Remarks:
	This report documents David Bielecki's treatment journey for David Bielecki David Bielecki with liver metastasis. His resilience and cooperation throughout this challenging time have been commendable. We wish him the best in his recovery process and hope for a successful long-term outcome.
